Detail akcie Nkarta Rg online

Business Summary: Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Nkarta Inc revenues was not reported. Net loss decreased 7% to $76.7M. Lower net loss reflects Biopharmaceutical segment loss decrease of 6% to $91M, United States segment loss decrease of 6% to $91M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.31 to -$1.04.